Abstract: A composition comprising at least two visually distinguishable phases, comprises at least one fatty phase with oil, at least one aqueous phase with hydrophilic gelling agent, and at least one compound chosen from N,N-dimethylglycine derivatives, alkyl(poly)glucosides, or a mixture thereof.

Abstract: The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: An elastomer has the general structure of: where: subscript a is 50-500, b is 1-10, c is 2-30, R1 has the structure: —CH2(CH2)nO(CH2)pCH(OH)(CH2)qNR2R2? where n, p and q are each independently 1-5 and R2 and R2? are independently selected from alkyl and hydroxyalkyl groups having 1-5 carbon atoms; where X is a crosslinker remnant bound to a siloxane unit corresponding to subscript c of a siloxane backbone polymer in addition to the one shown so that the crosslinker remnant in each occurrence is a reaction product with two siloxane backbone polymers, wherein the crosslinker is selected from a group consisting of primary organic dienes, divinyl siloxane and polyoxyalkylenes wherein at least two X components correspond to crosslinker remnants connecting the same two siloxane backbone polymers.

Abstract: A method for strengthening and repairing keratin fibres including providing a first—and a second crosslinking composition, wherein the first—crosslinking composition comprises an at least bi-functional Brønsted-base and the second—crosslinking composition comprises—an at least bi-functional organic acid, and a cosmetically acceptable carrier; applying the first—as well as the second—crosslinking composition to keratin fibres; and optionally mixing the first—crosslinking composition into a commercially available hair coloring or hair bleaching composition.

Abstract: The present invention relates to a hair cosmetic containing the following components (A) to (C): (A) a compound represented by the following general formula (1) or a salt thereof: wherein a broken line represents the presence or absence of a ? bond; R1 represents a hydroxy group or an acetoxy group; R2 represents a hydrogen atom or —COOR (R is a hydrogen atom, a methyl group, or an ethyl group); and R3 represents a hydrogen atom, an acetyl group, a methyl group, or an ethyl group; (B) a dimethylsilicone; and (C) an amino-modified silicone, the hair cosmetic satisfying such conditions that a mass ratio of the component (C) to the component (B) [(C)/(B)] is 0.3 or more and 3.0 or less; and a mass ratio of the component (A) to the component (B) and component (C) {(A)/[(B)+(C)]} is 1.0 or less.

Abstract: A biomaterial, particularly for tissue regeneration, includes an open, porous bioresorbable first material portion and a second material portion that is stiffer than the first material portion, wherein the volume fraction of the stiffer material is less than 30% of the total volume of the biomaterial, and the structural stiffness of the second material portion is at least 10 times greater than that of the first material portion.

Abstract: The present invention provides a novel lyophilized pharmaceutical composition that maintains the stability of a DNA plasmid while forming a uniform and elegant cake during lyophilization. The novel lyophilization formulation further allows uniform reconstitution of the DNA plasmid in a pharmaceutically acceptable solution, enabling complete recover of the active ingredients, minimizing partial loss of potency and allowing administration of the active ingredients in an accurate and consistent manner. Additionally provided herein include methods of making the lyophilized pharmaceutical composition and methods of administering the composition for treatment of various diseases.

Abstract: The invention relates to a composition comprising 5 to 100 wt. % of a structured aqueous phase wherein the composition contains 0.1 to 10 wt. % sericin by weight of water, said sericin having a proportion of beta-sheet in the secondary structure that exceeds 80%. It was found that sericin having a proportion of beta-sheet in the secondary structure that exceeds 80% is an excellent water structurant and can suitably be used to structure the aqueous phase of a wide range of products, such as cosmetic products, pharmaceutical products, food products and detergent compositions.

Abstract: A processing technique for creating nanowires and hierarchically porous micro/nano structures of ceramic materials is provided. The process includes evaporation of micron-sized water droplets containing dissolved organic salts on heated substrates followed by thermal decomposition of the deposited material. The micron-sized droplets may be generated by supercritical CO2 assisted nebulization, in which high-pressure streams of aqueous solution and supercritical CO2 are mixed, followed by controlled depressurization through a fine capillary. Rapid evaporation takes place on the heated substrates and structures are generated due to CO2 effervescence from the droplets and evaporation of water, along with the pinning of the three phase contact line. Depending on the mass deposited, a mesh of nano-wires or membrane-like structures may result. Sintering of the membrane-like scaffolds above the decomposition temperature of the organic salt creates nanopores within the structures, creating a dual hierarchy of pores.

Abstract: There are provided herein cosmetic and sanitary products comprising physiologic cooling compounds, selected 1,2-alkanediols, and tensides and/or UV filters.

Abstract: The present invention relates to a transdermal nano-carrier and, more specifically, to a nano-carrier having a chitosan-based nano-sponge structure. According to the present invention, as a nano-carrier having enhanced transdermal delivery on the basis of a complex containing chitosan is provided, it is possible to effectively deliver drugs, cosmetic materials, etc. into the skin.

Abstract: Provided are a cosmetic composition for inhibiting sebum hypersecretion and a method of inhibiting sebum hypersecretion using the same. According to the present invention, there may be provided the cosmetic composition of inhibiting and adjusting sebum secretion which is harmless to the human body with excellent skin safety and decreases activity of peroxisome proliferator activated receptor gamma (PPAR-?) to fundamentally decrease sebum overproduction, thereby providing the skin with an effective effect, and a method of using the same.

Abstract: A cosmetic composition including component (A), which is an aqueous gelling agent represented by general formula (1) described in the specification, and a component (B), which is a polymeric thickening agent, wherein the component (A) presents a viscosity of an aqueous solution containing 1 mass % of at 25° C. of 1,000 to 5,000 mPa·s and a clouding point of the aqueous solution containing 1 mass % of component (A) of 60° C. to 80° C., and has a weight average molecular weight of 10,000 to 30,000; a method for producing the aqueous gelling agent and a method for producing the cosmetic composition are provided.

Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.

Abstract: The invention relates to a method of making solid cleansing compositions which comprise a non-soap anionic surfactant, a carrier, an emulsifier and water. The method entails preparing an emulsion of the components at an elevated temperature using excess water and subjecting the emulsion to cooling and solidification, wherein the water content is reduced. The invention further relates to the emulsions and to the novel solid cleansing compositions formed therefrom.

Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP?. Further disclosed are formulations to increase the efficacy of the compounds that activate Tie-2 and inhibit HPTP?.

Abstract: Provided herein are methods and compositions useful for inhibiting microbe growth. The methods can comprise contacting the microbe with an antimicrobial agent and bicarbonate. In some embodiments, provided herein are methods for treating or preventing a microbial infection, comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent.

Abstract: A degradable, removable, pharmaceutical implant for the sustained release of one or more drugs in a subject, wherein the pharmaceutical implant is composed of a tube comprising an outer wall made of a degradable polymer completely surrounding a cavity, wherein the outer wall has a plurality of openings and wherein the cavity contains one or more sets of micro-particles, which micro-particles contain an active agent or a combination of two or more active agents, and wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings.

Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.